US2003104989A1PendingUtilityA1

Carrier polymers migrating into target organs and drug-containing polymers

Assignee: ONO PHARMACEUTICAL COPriority: Feb 27, 1998Filed: Oct 30, 2002Published: Jun 5, 2003
Est. expiryFeb 27, 2018(expired)· nominal 20-yr term from priority
A61K 47/645C08G 69/48C08G 69/10A61K 31/559
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Polymers derived from polymers represented by Formula (A) (d is 20˜500; and Rs, which may be the same or different, represent each H, alkyl or benzyl) by substituting a part or all of the consisting peptide bonds by (1) hydrazino-Glu (Formula B), and saccharide-modified Glu (Formula C) or by (2) hydorazino-Glu (Formula B), and saccharide-modified Glu (Formula C), and drug bonded Glu (Formula D). These polymers, which are carriers optionally bonded to drugs capable of migrating into target organs (cells), are useful as medicines.

Claims

exact text as granted — not AI-modified
1 . A polymer wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula (A)  
       
         
           
           
               
               
           
         
       
       (wherein, degree of polymerization d is 20˜500, R is hydrogen, C1˜6 alkyl or benzyl, with the proviso that each multiple R may be same or different.) are replaced with the group of the formula  
       
         
           
           
               
               
           
         
       
       (wherein  
       
         
           
           
               
               
           
         
       
       (wherein, G is a modified saccharide capable of connecting to hydrazine, m is 1 when  is a single bond and m is 0 when  is a double bond.)  
       (wherein, (1) group of the both formula (B) and (C) are essential substituents and when the number of replacement of group of the formula (C) is 2 or more, all the said group are the same.).  
     
     
         2 . A polymer wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula (A)  
       
         
           
           
               
               
           
         
       
       (wherein, all the symbols are defined as in claim  1 .) are replaced with the group of the formula  
       
         
           
           
               
               
           
         
       
       (wherein,  
       
         
           
           
               
               
           
         
       
       is defined as  claim 1 ,  
       
         
           
           
               
               
           
         
       
       (wherein, D is drug, n is 1 when  is a single bond, or n is 0 when  is a double bond.)  
       (wherein, (1) group of the both formula (C) and (D) are essential substituents, (2) the number of replacement of group of the formula (C) or (D) is 2 or more, all the said group of the formula (C) or (D) are the same and (3) the number of replacement of group of the formula (B) may be 0.).  
     
     
         3 . A polymer according to  claim 1  or  2 , wherein  
       
         
           
           
               
               
           
         
       
       is  
       
         
           
           
               
               
           
         
       
       (in each Formula, Q is saccharide chain containing 1˜10 saccharide.).  
     
     
         4 . The polymer according to  claim 1  or  2 , wherein  
       
         
           
           
               
               
           
         
       
       is  
       
         
           
           
               
               
           
         
       
     
     
         5 . A polymer according to  claim 2 , wherein D is a drug which is unstable in an alkaline condition.  
     
     
         6 . A polymer according to  claim 2 , wherein D is a drug possessing keto group.  
     
     
         7 . A polymer according to  claim 2 , wherein D is PGEs.  
     
     
         8 . A polymer according to  claim 2 , wherein  
       
         
           
           
               
               
           
         
       
       is  
       
         
           
           
               
               
           
         
       
     
     
         9 . A polymer according to  claim 2 , wherein D is a drug possessing carboxyl group.  
     
     
         10 . A polymer according to  claim 2 , wherein  
       
         
           
           
               
               
           
         
       
       is

Join the waitlist — get patent alerts

Track US2003104989A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.